1 Lee SJ, Kim JS, Song IU, et al. Poststroke restless

legs syndrome and lesion location:anatomical

considerations[J]. Mov Disord, 2009, 24:77-84.

2 夏建霞. Orexin-A兴奋大鼠皮层神经元的细胞机制

[D]. 重庆:第三军医大学, 2005.

3 Cl i nt on JM, Dav i s CJ, Ziel i n sk i MR, e t a l .

Bio c h emi c a l r e g u l a t io n of s l e e p a n d s l e e p

bioma rke r s [J ]. J Cl i n Sl e e p Me d , 2011, 7(5

Suppl):S38-S42.

4 吴逊. 全国第四届脑血管病学术会议纪要[J]. 卒中与

神经疾病, 1997, 4:51-55.

5 中华医学会糖尿病学分会.中国2型糖尿病防治指

南(2010年版)[J]. 中国医学前沿杂志(电子版), 2011,

4:54-109.

6 陈改玲, 刘国仗. 关于高血压定义与分类的修订建议

[J]. 中华老年多器官疾病杂志, 2003, 2:258-259.

7 苗海军, 周晓辉, 钟小兰. Alzheimer病危险因素病例

对照研究[J]. 新疆医科大学学报, 2006, 29:1146-1149.

8 Sil A, Barr G. Assessment of predictive ability of

Epworth scoring in screening of patients with sleep

apnoea[J]. Laryngol Otol, 2012, 126:372-379.

9 邓丽影. 脑卒中后觉醒障碍[J]. 中国现代神经疾病杂

志, 2013, 13:476-480.

10 Johnson PL, Samuels BC, Fitz SD, et al. Activation

of the orexin 1 receptor is a critical component of

CO2-mediated anxiety and hypertension but not

bradycardia[J]. Neuropsychopharmacology, 2012,

37:1911-1922.

11 Johnson PL, Shekhar A. An animal model of panic

vulnerability with chronic disinhibition of the

dorsomedial/perifornical hypothalamus[J]. Physiol

Behav, 2012, 107:686-698.

12 Bh a r a dwa j KN, Sp i t z C, Sh e k h a r A, e t a l .

Computational fluid dynamics of developing avian

outflow tract heart valves[J]. Ann Biomed Eng, 2012,

40:2212-2227.

13 Donner NC, Johnson PL, Fitz SD, et al. Elevated tph2

mRNA expression in a rat model of chronic anxiety[J].

Depress Anxiety, 2012, 29:307-319.

14 Shekhar A. Many faces of orexin/hypocretin[J]. Prog

Brain Res, 2012, 198:1-4.

15 Bolbecker AR, Shekhar A. Muscarinic agonists

and antagonists in schizophrenia:recent therapeutic

advances and future directions[J]. Handb Exp

Pharmacol, 2012, 208:167-190.

16 Shamoon H, Center D, Davis P, et al. Preparedness of

the CTSA's structural and scientific assets to support

the mission of the National Center for Advancing

Translational Sciences (NCATS)[J]. Clin Transl Sci,

2012, 5:121-129.

17 Hale MW, Shekhar A, Lowry CA. Stress-related

serotonergic systems:implications for symptomatology

of anxiety and affective disorders[J]. Cell Mol

Neurobiol, 2012, 32:695-708.

18 Pizza F, Magnani M, Indrio C, et al. The hypocretin

system and psychiatric disorders[J]. Curr Psychiatry Rep, 2014, 16:433.

19 Vogel CH. Assessment and approach to treatment in

post-stroke depression[J]. J Am Acad Nurse Pract,

1995, 7:493-497.

20 高文文, 秦升, 孔令超, 等. Hypocretin的研究新进展

[J]. 医学综述, 2010, 8:2425-2427.

21 de Lecea L, Huerta R. Hypocretin (orexin) regulation of

sleep-to-wake transitions[J]. Front Pharmacol, 2014, 5:16.

22 胡志安, 夏建霞. 觉醒系统的活动对学习记忆的影响

[J]. 第三军医大学学报, 2011, 33:1091-1094.

23 Kirchgessner AL, Liu M. Orexin synthesis and

response in the gut[J]. Neuron, 1999, 24:941-951.

24 Dalal MA, Schuld A, Haack M, et al. Normal plasma

levels of orexin A (hypocretin-1) in narcoleptic

patients[J]. Neurology, 2001, 56:1749-1751.

25 Kitamura E, Hamada J, Kanazawa N, et al. The effect of orexin-A on the pathological mechanism in the

rat focal cerebral ischemia[J]. Neurosci Res, 2010,

68:154-157.

26 Miossec P, Kolls JK. Targeting IL-17 and TH17 cells

in chronic inflammation[J]. Nat Rev Drug Discov,

2012, 11:763-776.

27 Huang SH, Frydas S, Kempuraj D, et al. Interleukin-17

and the interleukin-17 family member network[J].

Allergy Asthma Proc, 2004, 25:17-21.

28 Shichita T, Hasegawa E, Kimura A, et al. Peroxiredoxin

family proteins are key initiators of post-ischemic

inflammation in the brain[J]. Nat Med, 2012, 18:911-917.

29 Hoshi T, Kitagawa K, Yamagami H, et al. Relations

of serum high-sensitivity C-reactive protein and

interleukin-6 levels with silent brain infarction[J].

Stroke, 2005, 36:768-772.